Systematic re-annotation of 191 genes associated with early-onset epilepsy unmasks de novo variants linked to Dravet syndrome in novel SCN1A exons
Charles A. StewardiD, Jolien RooversiD, Marie‐Marthe SuneriD, José M. GonzáleziD, Barbara Uszczyńska-RatajczakiD, Dmitri Davidovich PervouchineiD, Stephen F. FitzgeraldiD, Margarida ViolaiD, Hannah StambergeriD, Fadi F. HamdaniD, Berten CeulemansiD, Patricia Leroy, Caroline NavaiD, Anne Fabienne LepineiD, Electra TapanariiD, Don R. KeilleriD, Stephen J. AbbsiD, Alba Sanchis‐JuaniD, Detelina GrozevaiD, Anthony S. RogersiD, James Wright, Jyoti Sharma ChoudharyiD, Mark DiekhansiD, Roderic GuigóiD, Robert PetryszakiD, , Adam FrankishiD
Abstract
The early infantile epileptic encephalopathies (EIEE) are a group of rare, severe neurodevelopmental disorders, where even the most thorough sequencing studies leave 60-65% of patients without a molecular diagnosis. Here, we explore the incompleteness of transcript models used for exome and genome analysis as one potential explanation for lack of current diagnoses. Therefore, we have updated the GENCODE gene annotation for 191 epilepsy-associated genes, using human brain-derived transcriptomic libraries and other data to build 3,550 novel putative transcript models. The extended transcriptional footprint of these genes allowed for 294 intronic or intergenic variants, found in human mutation databases, to be reclassified as exonic, while a further 70 intronic variants were reclassified as splice-site proximal. Using SCN1A as a case study due to its close phenotype/genotype correlation with Dravet syndrome, we screened 122 people with Dravet syndrome, or a similar phenotype, with a panel of novel exon sequences representing eight established genes and identified two de novo SCN1A variants that now, through improved gene annotation can be ascribed to residing among novel exons. These two (from 122 screened patients, 1.6%) new molecular diagnoses carry significant clinical implications. Furthermore, we identified a previously-classified SCN1A intronic Dravet-associated variant that now lies within a deeply conserved novel exon. Our findings illustrate the potential gains of thorough gene annotation in improving diagnostic yields for genetic disorders. We would expect to find new molecular diagnoses in our 191 genes that were originally suspected by clinicians for patients, with a negative diagnosis.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Harnessing Mondo and the ILAE Classification for Curation and Analysis of 71,942 epilepsy patient variants
Alina Ivaniuk, Tobias Brünger, … Dennis Lal·medRxiv·Jan 7, 2025
- Clinical signatures of genetic epilepsy precede diagnosis in electronic medical records of 32,000 individuals
Peter D. Galer, Shridhar Parthasarathy, … Ingo Helbig·Genetics in MedicinePeer-reviewed·Jul 14, 2024
- The SCN1A Philadelphia variant - a gain-of-function mutation causing an early-onset epileptic encephalopathy
Jérôme Clatot, Shridhar Parthasarathy, … Ingo Helbig·bioRxiv·Jun 29, 2022
- De novo Variants In Neurodevelopmental Disorders With Epilepsy
Henrike Heyne, Tarjinder Singh, … Johannes R. Lemke·Nature GeneticsPeer-reviewed·Jun 22, 2018
- Axonopathy and altered synaptic development in early hippocampal epileptogenesis of Dravet syndrome
Nikolas Layer, Peter Müller, … Thomas V. Wuttke·bioRxiv·Oct 4, 2023
- Genome sequencing boosts diagnostic yield for the developmental and epileptic encephalopathies
Jacob E. Munro, Harshini Thiyagarajah, … Michael S. Hildebrand·medRxiv·Apr 28, 2026